Fenwick & West represented Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, in its $120 million financing.
The round was led by Foresite Capital with participation from Bain Capital Life Sciences, Boxer Capital (Tavistock Group), EcoR1 Capital, Redmile Group, Wellington Management Company and an undisclosed investor, as well as Nurix’s founding investors The Column Group and Third Rock Ventures.
The funding will be used by Nurix to advance its targeted protein modulation therapeutics into clinical development. More information can be obtained from the company’s announcement.
The Fenwick transaction team includes corporate partner Michael Brown and associates Katherine Duncan, Melody Khorsandi, Annie Omata and Alyssa Zhang.